Route of Agent Administration
ALZET minipumps can be used for systemic administration when implanted subcutaneously or intraperitoneally. They can be attached to a catheter for intravenous, intra-arterial, or intrathecal infusion. ALZET pumps can also be cannected to brain cannulae for delivery to the cerebral ventricles or brain tissue. ALZET pumps have been used for targeted delivery of test agents to a wide variety of sites, including the spinal cord, spleen, liver, organ or tissue transplants, wound healing sites, etc.
Examples of this research are included in the reference lists* shown below. If you are interested in a specific agent not listed below, check the index by Agent Administered.
*Some of these bibliographies may be large and take a short while to display. These bibliographies are updated frequently. As the references are listed most recent first, you may wish to truncate your printing to ten pages or less.
Looking for references? We can help!
Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 16,000 publications! We can perform a custom search for references relevant to your research.
- Ensure around-the-clock exposure to test agents at predictable levels
- Permit continuous administration of short half-life proteins and peptides
- Provide a convenient method for the chronic dosing of laboratory animals
- Minimize unwanted experimental variables and ensure reproducible, consistent results
- Eliminate the need for nighttime or weekend dosing
- Reduce handling and stress to laboratory animals
- Small enough for use in mice or very young rats
- Allow for targeted delivery of agents to virtually any tissue
- Cost-effective research tool
What researchers are saying...
“Nonspecific toxicity is a common problem associated with in vivo application of antisense oligonucleotides.However, by employing certain strategies including the use of partial rather than complete phosphorothioate modification, reducing the length of the oligonucleotide, and using a steady continuous infusion rather than bolus injections, we were able to minimize such toxicity (Van Kampen & Stoessl, 2000a).” (p. 309) Van Kampen et al., Neuroscience 2003;116:307-314.